Stephen Hornak, MD
Cardiovascular Disease · Richmond, INNPI 1871685990
Payments from drug & device makers
Across 370 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$953
- Novartis$928
- Johnson & Johnson$692
- Amgen$468
- Pfizer$466
- E.r. Squibb & Sons, L.L.C.$265
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,243100%
- Education$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $953 |
| Novartis | 63 | $928 |
| Johnson & Johnson | 49 | $692 |
| Amgen | 30 | $468 |
| Pfizer | 31 | $466 |
| E.r. Squibb & Sons, L.L.C. | 18 | $265 |
| Arbor Pharmaceuticals, Inc. | 2 | $228 |
| Boehringer Ingelheim | 14 | $215 |
| Sanofi-aventis U.S. LLC | 14 | $196 |
| Amarin Pharma, Inc. | 11 | $180 |
| Boston Scientific | 5 | $167 |
| Merck | 8 | $164 |
| Abbott | 7 | $146 |
| Scpharmaceuticals Inc. | 6 | $136 |
| Novo Nordisk | 5 | $104 |
| Alnylam Pharmaceuticals Inc. | 4 | $83 |
| Abiomed | 3 | $78 |
| Chiesi USA, Inc. | 5 | $75 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $70 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $61 |
| Bayer | 3 | $55 |
| Impulse Dynamics (USA) Inc. | 2 | $55 |
| Edwards Lifesciences | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 4 | $49 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Lexicon Pharmaceuticals, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 3 | $44 |
| Altathera Pharmaceuticals LLC | 2 | $31 |
| Medtronic | 1 | $30 |
| Tactile Systems Technology Inc | 2 | $30 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Cvrx, Inc. | 2 | $21 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Gilead | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edarbi$228
- WATCHMAN Access System$103
How this compares
$6,270 in reported general payments places this provider in the 60th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 626 | $609,025 |
| VyndaqelTafamidis Meglumine | 12 | $276,027 |
| XareltoRivaroxaban | 219 | $231,328 |
| Repatha SureclickEvolocumab | 222 | $188,090 |
| EntrestoSacubitril/Valsartan | 171 | $176,265 |
| JardianceEmpagliflozin | 120 | $117,803 |
| BrilintaTicagrelor | 106 | $70,931 |
| MultaqDronedarone Hcl | 49 | $48,333 |
| FarxigaDapagliflozin Propanediol | 56 | $45,595 |
| Praluent PenAlirocumab | 52 | $39,049 |
| VascepaIcosapent Ethyl | 89 | $38,376 |
| OzempicSemaglutide | 11 | $10,366 |
| Ranolazine ErRanolazine | 88 | $10,029 |
| Nebivolol Hcl | 119 | $8,475 |
| Bisoprolol Fumarate | 443 | $6,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndaqel | $466 | $885,051638 claims |
| Johnson & JohnsonXarelto | $692 | $231,328219 claims |
| NovartisEntresto | $928 | $176,265171 claims |
| Boehringer IngelheimJardiance | $215 | $117,803120 claims |
| AstraZenecaBrilinta, Farxiga | $953 | $116,525162 claims |
| Sanofi-aventis U.S. LLCMultaq | $196 | $48,33349 claims |
| Novo NordiskOzempic | $104 | $10,36611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Richmond
- John McGintyRichmond$3.7M
- Rubinder DabRichmond$544K
- Steven SteinhublLafayette$2.4M
- Ravi BhagwatMunster$2.2M
- Mohan KesaniMunster$1.2M
- Vijay MehtaElkhart$925K
- William CollisFort Wayne$842K
- Atul ChughIndianapolis$775K
- Noel DasguptaIndianapolis$744K
- Wail AsfourMunster$736K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.